NASDAQ:BLLN Billiontoone (BLLN) Stock Price, News & Analysis $97.94 -0.71 (-0.72%) Closing price 04:00 PM EasternExtended Trading$98.36 +0.42 (+0.42%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Billiontoone Stock (NASDAQ:BLLN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Billiontoone alerts:Sign Up Key Stats Today's Range$94.45▼$99.0750-Day Range$91.65▼$149.9752-Week Range$61.96▼$150.44Volume575,347 shsAverage Volume537,112 shsMarket Capitalization$4.50 billionP/E Ratio139.91Dividend YieldN/APrice Target$126.71Consensus RatingModerate Buy Company Overview BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical. BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics. Its technology aims to improve accuracy in detecting fetal aneuploidies, microdeletions, and single-gene disorders from maternal blood samples by reducing measurement noise and enabling precise digital quantification. The company provides testing services and partners with clinical laboratories, healthcare providers, and research organizations to implement its assays in clinical and research settings. In support of clinical adoption, BillionToOne focuses on analytical validation, clinical studies, and building laboratory processes that integrate its single-molecule counting approach into standard diagnostic pipelines. The company positions its platform as complementary to existing sequencing and molecular methods, emphasizing improved detection of low-frequency variants and potential reductions in false positives that can drive follow-up invasive procedures. BillionToOne serves the healthcare and clinical diagnostics market, primarily through collaborations and laboratory channels. Its management and scientific teams are oriented toward translating advanced genomic measurement techniques into deployable clinical tests, with ongoing efforts to expand the clinical utility and accessibility of its assays through partnerships and regulatory and clinical validation activities.AI Generated. May Contain Errors. Read More Billiontoone Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreBLLN MarketRank™: Billiontoone scored higher than 91% of companies evaluated by MarketBeat, and ranked 59th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingBilliontoone has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 6 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialBilliontoone has a consensus price target of $126.71, representing about 29.4% upside from its current price of $97.94.Amount of Analyst CoverageBilliontoone has only been the subject of 4 research reports in the past 90 days.Read more about Billiontoone's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth23.91% Earnings GrowthEarnings for Billiontoone are expected to grow by 23.91% in the coming year, from $0.92 to $1.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Billiontoone is 139.91, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.42.Price to Earnings Ratio vs. SectorThe P/E ratio of Billiontoone is 139.91, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 268.64.Price to Book Value per Share RatioBilliontoone has a P/B Ratio of 9.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.39% of the float of Billiontoone has been sold short.Short Interest Ratio / Days to CoverBilliontoone has a short interest ratio ("days to cover") of 3.38, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Billiontoone has recently decreased by 20.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBilliontoone does not currently pay a dividend.Dividend GrowthBilliontoone does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.16 News SentimentBilliontoone has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Billiontoone this week, compared to 4 articles on an average week.Search Interest13 people have searched for BLLN on MarketBeat in the last 30 days. This is an increase of 160% compared to the previous 30 days.MarketBeat Follows5 people have added Billiontoone to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Billiontoone insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,496,861.00 in company stock.Percentage Held by Insiders50.22% of the stock of Billiontoone is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsBilliontoone has minimal institutional ownership at this time.Read more about Billiontoone's insider trading history. Receive BLLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Billiontoone and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BLLN Stock News HeadlinesBTIG Research Cuts Billiontoone (NASDAQ:BLLN) Price Target to $130.00August 9 at 2:48 AM | americanbankingnews.comJPMorgan Chase & Co. Lowers Billiontoone (NASDAQ:BLLN) Price Target to $130.00August 8 at 3:19 AM | americanbankingnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.August 11 at 1:00 AM | Profits Run (Ad)Billiontoone (NASDAQ:BLLN) Lowered to Hold Rating by Wall Street ZenAugust 8 at 2:14 AM | americanbankingnews.comBilliontoone (NASDAQ:BLLN) Shares Gap Down on Insider SellingAugust 8 at 1:40 AM | americanbankingnews.comBillionToOne: A Softer Quarter After Heightened ExpectationsAugust 7, 2026 | seekingalpha.comInsider Selling: Billiontoone (NASDAQ:BLLN) Insider Sells 4,000 Shares of StockAugust 5, 2026 | insidertrades.comBilliontoone (NASDAQ:BLLN) Insider Shan Riku Sakakibara Sells 8,000 SharesJuly 14, 2026 | insidertrades.comSee More Headlines BLLN Stock Analysis - Frequently Asked Questions How have BLLN shares performed this year? Billiontoone's stock was trading at $81.84 on January 1st, 2026. Since then, BLLN stock has increased by 19.7% and is now trading at $97.94. How were Billiontoone's earnings last quarter? Billiontoone, Inc. (NASDAQ:BLLN) issued its earnings results on Wednesday, August, 5th. The company reported $0.15 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.15. The business had revenue of $109.45 million for the quarter. Billiontoone had a trailing twelve-month return on equity of 9.96% and a net margin of 8.04%. Read the conference call transcript. When did Billiontoone IPO? Billiontoone (BLLN) raised $203 million in an initial public offering on the week of November 3rd 2025. The company issued 3,900,000 shares at a price of $49.00-$55.00 per share. J.P. Morgan, Piper Sandler, Jefferies, William Blair, Stifel, Wells Fargo Securities and BTIG served as the underwriters for the IPO. Who are Billiontoone's major shareholders? Top institutional shareholders of Billiontoone include Wasatch Advisors LP (1.13%) and Thrive Wealth Management LLC. Insiders that own company stock include Shan Riku Sakakibara, Bosch John Roderick Ten, Nancy Joann Johnson, Oguzhan Atay, Oguzhan Atay and David Tsao. View institutional ownership trends. How do I buy shares of Billiontoone? Shares of BLLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/05/2026Today8/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNASDAQ:BLLN CIK2070849 Webwww.billiontoone.com Phone(650) 460-2551FaxN/AEmployees620Year Founded2016Price Target and Rating Average Price Target for Billiontoone$126.71 High Price Target$150.00 Low Price Target$90.00 Potential Upside/Downside+29.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)$0.70 Trailing P/E Ratio139.91 Forward P/E Ratio106.46 P/E GrowthN/ANet Income$7.45 million Net Margins8.04% Pretax Margin9.54% Return on Equity9.96% Return on Assets5.35% Debt Debt-to-Equity Ratio0.17 Current Ratio11.69 Quick Ratio11.31 Sales & Book Value Annual Sales$397.41 million Price / Sales11.34 Cash Flow$0.34 per share Price / Cash Flow288.53 Book Value$10.48 per share Price / Book9.35Miscellaneous Outstanding Shares45,995,000Free Float22,896,000Market Cap$4.50 billion OptionableN/A BetaN/A Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:BLLN) was last updated on 8/11/2026 by MarketBeat.com Staff. From Our PartnersReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Billiontoone, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Billiontoone With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.